Clinical Trial: BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108309) titled 'BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer' on Aug. 04.

Brief Summary: To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Study Start Date: July 15, 2024

Study Type: INTERVENTIONAL

Condition: Triple Negative Breast Cancer

Intervention: BIOLOGICAL: BCD-236

as an intravenous infusion

DRUG: Chemotherapy

CHT (at the investigator's discretion):

Recruitment Status:...